Pioglitazone to reduce restenosis after bare-metal stent placement?
Nissen
Steven E
SE
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D049109:Cell Proliferation / Q000187:drug effects; D023903:Coronary Restenosis / Q000209:etiology / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008670:Metals; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D000077205:Pioglitazone; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D015607:Stents; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology
D007004:Hypoglycemic Agents; D008670:Metals; D045162:Thiazolidinediones; D000077205:Pioglitazone